Shopping Cart
- Remove All
- Your shopping cart is currently empty
PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 is an effective inhibitor of inhaled p38 MAPK. PF-03715455 displays some selectivity for p38α over p38β (respective IC50: 0.88 and 23 nM). PF-03715455 has the potential for the treatment of COPD.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $5,140 | 10-14 weeks |
Description | PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 is an effective inhibitor of inhaled p38 MAPK. PF-03715455 displays some selectivity for p38α over p38β (respective IC50: 0.88 and 23 nM). PF-0371545 |
Targets&IC50 | p38β:23 nM, p38α:0.88 nM |
In vitro | PF-03715455 is a moderate inhibitor of CYP1A2, CYP2C19, and CYP2D6, and a potent inhibitor of CYP2C9 and CYP3A4[2]. |
In vivo | PF-03715455 treatment displays that the Vss is 0.19 L/kg and T1/2 is 1 hour [2]. |
Molecular Weight | 700.27 |
Formula | C35H34ClN7O3S2 |
Cas No. | 1056164-52-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.